Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II p210-b3a2 peptide vaccine study in chronic myeloid leukemia with residual molecular disease on imatinib
2006-006189-40Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Apr 2007
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CMLVAX100 and imatinib in chronic myelogenous leukemia (CML), sponsored by GIMEMA. Primary endpoint: Molecular response rate at 6 months with persistence at 9 months. Started Apr 2007; status: completed.
02
Drugs
CMLVAX100imatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2006-006189-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006189-40.